Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Public ClinicalTrials.gov record NCT02595866. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Study identification
- NCT ID
- NCT02595866
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 58 participants
Conditions and interventions
Conditions
- AIDS-Related Non-Hodgkin Lymphoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- HIV Infection
- Hepatocellular Carcinoma
- Kaposi Sarcoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Non-Hodgkin Lymphoma
- Recurrent Classic Hodgkin Lymphoma
- Recurrent Malignant Neoplasm
- Refractory Classic Hodgkin Lymphoma
- Refractory Malignant Neoplasm
- Stage III Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Unresectable Melanoma
Interventions
- Antiretroviral Therapy Drug
- Biopsy Procedure
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Pembrolizumab Biological
- Positron Emission Tomography Procedure
Drug · Procedure · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 3, 2016
- Primary completion
- Oct 3, 2023
- Completion
- Mar 24, 2024
- Last update posted
- Aug 8, 2024
2016 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Cancer Center | Birmingham | Alabama | 35233 | — |
| Zuckerberg San Francisco General Hospital | San Francisco | California | 94110 | — |
| UCSF Medical Center-Parnassus | San Francisco | California | 94143 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Louisiana State University Health Science Center | New Orleans | Louisiana | 70112 | — |
| University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | — |
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York | 10016 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| FHCC South Lake Union | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02595866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 8, 2024 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02595866 live on ClinicalTrials.gov.